“ Historically, a special sympathy of the physiological mechanism of erections restricted the discourse of ED to vacuum-constriction devices,
medicine implants, intracavernosal injections, and intraurethral suppositories.4 Since its advent, the category
of agents known as type-5 phosphodiesterase (PDE5) inhibitors has revolutionized the management of
ED. PDE5 inhibitors make turn the first-contrast therapy for ED, as suggested by the American Urological Connection (AUA) and the European Tie-up of Urogenital medicine http://lm360.us/ ”